Psoriatic Arthritis News

Despite a low number of major adverse cardiovascular events overall, patients with psoriatic arthritis who newly start IL-12/23 or IL-17 inhibitors have a greater cardiovascular risk than those who begin TNF inhibitors, according to data.

Guselkumab 100 mg administered every 4 or 8 weeks produced “meaningful and sustained” improvements in fatigue through 1 year in patients with psoriatic arthritis, according to data published in Arthritis & Research & Therapy.

This past spring, two studies shed light on how some of the largest clinician organizations and publishers in rheumatology, including the American College of Rheumatology and EULAR, have failed to provide adequate training materials or clear guidelines when it comes to caring for patients of color.

Both ustekinumab and TNF inhibitors demonstrate significant improvement in psoriatic arthritis disease activity, with similar positive results in minimal and low disease activity, and remission, after 6 months, according to data.

Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with psoriatic arthritis, versus TNF-inhibitor monotherapy, according to data published in the Annals of the Rheumatic Diseases.

Guselkumab administered once every 4 or 8 weeks improved axial outcomes in patients with psoriatic arthritis who have sacroiliitis through week 52, according to data published in The Lancet Rheumatology.

On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira.

Patients with psoriasis or psoriatic arthritis treated with ustekinumab demonstrated a 1.4- to 3-times lower risk for hospitalization with serious infections than those who received other biologics or apremilast, according to data.

Risankizumab is linked to significantly greater improvements in psoriatic arthritis signs and symptoms than placebo in patients with an inadequate response, or intolerance, to other drugs, according to a speaker at the EULAR 2021 Congress.

Upadacitinib maintains its efficacy over 56 weeks in patients with psoriatic arthritis who had a prior inadequate response to at least one biologic disease-modifying antirheumatic drug, according to data presented at the EULAR 2021 Virtual Congress.